REG - Abingdon Health PLC - Trading Update

Abingdon HealthAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260115:nRSO9539Oa&default-theme=true

RNS Number : 9539O  Abingdon Health PLC  15 January 2026

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the
publication of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public domain.

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Trading Update

45% increase in H1 FY26 revenues

Confident commercial outlook

 

York, U.K.  15 January 2026: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and regulatory services provider for
rapid diagnostic tests and med-tech, provides its half-year trading update for
the six months ended 31 December 2025.

 

Total revenues in the six months ended 31 December 2025 ("H1 FY26") grew by
45% to £4.5 million (H1 FY25: £3.1 million), driven by several significant
commercial contracts announced during the past year. H1 FY26 includes an
element of grant-funded contract development revenue which will be presented
in 'other operating income' as required by accounting standards.

 

Cash and cash equivalents at 31 December 2025 were £3.6 million (30 June
2025: £1.9 million).  This  followed the Company's recent fundraise in
October 2025
(https://www.londonstockexchange.com/news-article/ABDX/result-of-placing-and-notice-of-gm/17277463)
which raised £3.2m net of expenses to accelerate expansion operations in the
USA and enhance working capital required in new higher revenue-generating
projects including recent major contract wins and future anticipated pipeline
opportunities.

 

Outlook

Looking ahead to the second half of the financial year the Board remains
confident in the commercial outlook for the Company, supported by several
significant contracts announced and commenced during H1 FY26. As in prior
years, revenue for the financial year ending 30 June 2026 ("FY26") is expected
to be weighted towards the second half of the financial year.

 

The Board is maintaining its revenue guidance for FY26, including grant-funded
income, in line with market expectations of £12.6 million (£12.2m plus
£0.4m grant funded revenue). The mix of forecasted revenue for H2 has changed
as the Group executes on its recently announced contract wins. The expected
revenue from current customer Find Out From Home (FOFH) is now expected to be
realised in FY27 as FOFH performs a fundraising process.   Despite that
adjustment, the Board remains confident in the revenue outlook for FY26.

 

EBITDA for FY26 will be driven in part by new customer wins and by the speed
of acceleration of USA expansion, where the Company is currently increasing
its lateral flow development and manufacturing footprint at its Madison, WI
facilities to satisfy customer demand. The Board anticipates H2 FY26 to be
profitable and operating cash flow positive whilst the outturn for the year
will depend largely on anticipated continued commercial progress throughout
H2.The Company expects to report its results for H1 FY26 in March 2026, where
a further update will be provided.

 

Investor presentation

Dr Chris Hand, Executive Chairman, will be presenting this evening, Thursday
15 January 2026, at the Proactive One2One Investor Forum in London. Further
information may be found at Proactive Investors
(https://www.proactiveinvestors.co.uk/register/event_details/466) and the
investor presentation will be made available in the investor relations section
of Abingdon Health's website after the event.

 

 

Chris Hand, Executive Chairman, commented: "I am pleased to report substantial
revenue growth in the first six months of the financial year, and the outlook
for the rest of FY26 and beyond remains positive. We have made significant
commercial and operational progress via our integrated end-to-end CDMO and CRO
service offering which has supported us in securing several major contracts as
previously announced, and this momentum is expected to continue in the coming
year and beyond."

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                                     Via Walbrook PR

 Tom Hayes, CFO

 Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)                Tel: +44 (0)20 7220 0500
 Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format.  Abingdon Health
has the internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing, including companion diagnostics,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
and IVDeology, provide a broad range of regulatory services to the in vitro
diagnostic and wider medical device industry, to support customers in bringing
products to market across a range of territories including the USA, EU and the
UK.  Its consultancy services range from design, implementation and
maintenance of quality management systems, preparation of technical files for
regulatory approvals, part-time and interim management support, auditing both
internal and external, management reviews and presentations, training and
mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers
analytical testing and performance evaluation to generate the required
technical and data for regulatory approval for lateral flow and other in vitro
diagnostic assays from its Doncaster, England facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFLFITLSISLIR



            Copyright 2019 Regulatory News Service, all rights reserved